578 results about "Protein antibody" patented technology

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

The invention discloses a pseudorabies virus variant gD protein as well as a preparation method and application thereof. The amino acid sequence of the pseudorabies virus variant gD protein is shown as a sequence 1 in a sequence table, and the nucleotide sequence of the pseudorabies virus variant gD protein is shown as a sequence 2 in the sequence table. The pseudorabies virus variant gD protein is used for indirect ELISA, can be used for detecting whether a pseudorabies virus variant gD protein antibody exists in pig blood or not, and is simple, convenient and rapid in detection, high in specificity, high in sensitivity, accurate and reliable. The pseudorabies virus variant gD protein can be prepared into a subunit vaccine, can be induced to generate a high-level anti-pseudorabies virus variant neutralizing antibody after immunizing a pig, has the advantages of strong immunogenicity, high safety and matching with a current epidemic strain, can distinguish vaccine immunization and wild virus infection animals through differential diagnosis, and has a wide application prospect. The method can be used for preventing and controlling the propagation and prevalence of pseudorabies. The gD protein of the pseudorabies virus variant can be used for detecting and diagnosing pseudorabies and preventing pseudorabies, and has good production and application prospects in development of novel diagnostic reagents and subunit vaccines of pseudorabies viruses.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

The invention belongs to the technical field of biological detection, and relates to an antibody composition aiming at pTau217 protein detection and application thereof, and the antibody composition aiming at pTau217 protein detection comprises a target pTau217 protein antibody and a target Tau protein C-terminal antibody. Meanwhile, based on the antibody composition aiming at pTau217 protein detection, the invention further provides a kit for early diagnosis of the Alzheimer's disease. The invention provides an antibody composition aiming at pTau217 protein detection, which is stronger in detection specificity and higher in sensitivity, and an application of the antibody composition.

The invention discloses an African swine fever virus p30 protein antibody and application thereof. When the African swine fever virus p30 protein antibody is used for a competitive ELISA method, a serum sample with the p30 antibody after African swine fever virus infection can be rapidly and accurately detected, the detection time is shortened, the detection steps are simplified, the African swine fever virus p30 protein antibody has the characteristics of rapidness and high-throughput detection, and a reliable immunological technology is provided for rapidly and efficiently detecting African swine fever virus infection.

Herein is reported an anti-TREM2 / Abeta protein antibody comprising a first binding site binding to human TREM2 comprising a heavy chain variable domain comprising a HVR-H1 of SEQ ID NO: 305, a HVR-H2 of SEQ ID NO: 306 and a HVR-H3 of SEQ ID NO: 307, and a light chain variable domain comprising a HVR-L1 of SEQ ID NO: 309, a HVR-L2 of SEQ ID NO: 310 and a HVR-L3 of SEQ ID NO: 311 (TREM2 3295), or a heavy chain variable domain comprising a HVR-H1 of SEQ ID NO: 329, a HVR-H2 of SEQ ID NO: 330 and a HVR-H3 of SEQ ID NO: 331, and a light chain variable domain comprising a HVR-L1 of SEQ ID NO: 333, a HVR-L2 of SEQ ID NO: 334 and a HVR-L3 of SEQ ID NO: 335 (TREM2 3306), and a second binding site binding to human Abeta protein comprising a heavy chain variable domain comprising a HVR-H1 of SEQ ID NO: 09, a HVR-H2 of SEQ ID NO: 10 and a HVR-H3 of SEQ ID NO: 11, and in the light chain variable domain a HVR- L1 of SEQ ID NO: 13, a HVR-L2 of SEQ ID NO: 14 and a HVR-L3 of SEQ ID NO: 15 (Abeta 8675).

The present invention discloses an integrated biosensor platform based on microneedles and hydrogels and its application in detecting monkeypox virus, wherein the platform comprises a three-electrode microneedle, a hydrogel, a burning needle and a micro-electrochemical workstation. The microneedle electrode of the working electrode is combined with a nanoenzyme and an A29 protein antibody, and the monkeypox virus in the sample is extracted by the specific binding of the antibody with the monkeypox virus; the burning needle is used to connect the three-electrode microneedle and the micro-electrochemical workstation and transmit electrochemical signals. After the three-electrode microneedle is inserted into the hydrogel, the nanoenzyme catalyzes the TMB contained in the hydrogel and generates a blue oxidation product, thereby generating an electrochemical signal, which is collected by the micro-electrochemical workstation through the burning needle, and the electrochemical signal is collected through Bluetooth and a hydrogel colorimetric image is obtained, thereby realizing the detection of monkeypox virus. The integrated biosensor platform of the present invention has a low detection limit and has broad application prospects in the rapid on-site detection of monkeypox virus.

The invention discloses an antibody for resisting protein of a growth stimulation expression gene 2 and application of the antibody, and relates to the field of antibodies. The anti-GST2 protein antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of GST2 protein, and has good activity and sensitivity.

In alternative embodiments, provided are chimeric, synthetic or recombinant antibodies (Ab) against the human homologous box NKX-2. 1 (also known as NK2 homologous box 1, or thyroid transcription factor 1 (TTF-1)) protein, including articles of manufacture and kits comprising them, and methods of making and using them, including, for example, their use in the detection or diagnosis and treatment of cancer. In alternative embodiments, an anti-NKX-2. 1 (TTF-1) antibody provided herein is used with an agent for determining whether NKX-2. 1 (TTF-1) expression or activity is present, reduced or deleted; or the sensitivity of the specific binding of the Ab or the antigen (Ag) binding fragment or protein (ABP) or the monomer or dimer ABP provided by the invention with the squamous cell carcinoma cells is lower than the sensitivity of the specific binding with the adenocarcinoma cells (or binding with lower affinity), so that false positives of the squamous cell carcinoma are less, and the positive recognition of the lung adenocarcinoma is better.

The invention discloses an anti-norovirus VP1 protein antibody and application thereof, discloses an anti-VP1 protein antibody, a fragment or a fusion protein thereof, comprising a heavy chain variable region and a light chain variable region, and also provides a separated polynucleotide, a carrier, a host cell and a pharmaceutical composition comprising the anti-VP1 protein antibody, the fragment or the fusion protein thereof, the invention also discloses a method for preparing the anti-VP1 protein antibody, the fragment or the fusion protein thereof, a method for detecting the existence or the amount of the VP1 protein or the norovirus in a sample, and an application of the anti-VP1 protein antibody, the fragment or the fusion protein in a corresponding medicament for treating, preventing or relieving diseases or symptoms responding to VP1 protein inhibition, and a method for preparing the anti-VP1 protein antibody, the fragment or the fusion protein and the method for detecting the existence or the amount of the VP1 protein or the norovirus in a sample. The invention also relates to application in production of a product for detecting the VP1 protein or the norovirus.

The application provides a virus combined detection immunochromatography test paper, a detection pen and a detection product, and relates to the technical field of immunochromatography test paper. The virus combined detection immunochromatography test paper can detect the novel coronavirus, the influenza A virus and the influenza B virus in a three-in-one manner. The sample binding pad of the immunochromatography test paper is coated with labeled antibodies, including a first influenza A virus antibody, a first influenza B virus antibody, a first novel coronavirus antibody and a first human internal reference protein antibody, and each labeled antibody is labeled with a different color of label. The immunochromatography test paper adopts a double-antibody sandwich principle, and the second influenza A virus antibody, the second influenza B virus antibody and the second novel coronavirus antibody are coated on different detection lines in the detection area. The immunochromatography test paper and the detection pen solve the problems of complex operation and difficult interpretation of the three-in-one detection product of the novel coronavirus, the influenza A virus and the influenza B virus in the prior art.

The invention discloses an antibody for resisting dengue virus or NS1 protein thereof and application of the antibody, and relates to the field of antibodies. The antibody for resisting the dengue virus or the NS1 protein of the dengue virus comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of the dengue virus or the NS1 protein of the dengue virus, and has good affinity or activity.

Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

The invention provides a fusion protein for detecting an aquaporin 4 antibody as well as a preparation method and application of the fusion protein, and belongs to the technical field of aquaporin 4 antibody detection. The nucleotide sequence of the fusion protein is shown as SEQ ID NO.5. The fusion protein is used as a coating antigen, M1 type and M23 type aquaporin 4 can be detected at the same time, and the sensitivity and the accuracy of detecting an aquaporin 4 antibody are high, and the repeatability is good. When the kit is used for the aquaporin 4 antibody, the detection method is simple and rapid, and the kit is suitable for clinical and scientific research large-scale screening of the aquaporin 4 antibody.

Aspects of the disclosure relate to methods and compositions (e.g., kits) for detecting anti-repeat-associated non-ATG (RAN) protein antibodies in a subject (e.g., a subject that has been administered a therapeutic anti-RAN protein antibody or a vaccine against a disease or disorder associated with RAN protein expression, translation, and / or accumulation, for example amyotrophic lateral sclerosis (ALS) and / or frontotemporal dementia (FTD)). In some embodiments, methods described by the disclosure comprise detecting one or more anti-RAN protein antibodies in a biological sample obtained from a subject by an electrochemiluminescence-based immunoassay using one or more target di-amino acid repeat peptides. In some embodiments, the disclosure relates to kits comprising one or more di-amino acid repeat peptides and an electrochemiluminescence-based immunoassay plate and / or reagents.

Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ 5 ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.

The invention relates to the technical field of nano-drug presentation systems, in particular to a TCR (T cell receptor) nano-vesicle antibody with both T cell redirection and immunosuppression reversal as well as a preparation method and application of the TCR nano-vesicle antibody. The TCR nano-vesicle antibody comprises a vesicle formed by a liposome and a cell membrane; tCR protein, a PD-1 antibody and a CD3 antibody are loaded on the vesicles. The nano vesicle antibody has the functions of T cell redirection and immunosuppression reversion; the difficulty of low stability of the soluble TCR is overcome; the polypeptide can be rapidly enriched in tumor tissues through tumor specificity TCR, and CD8 + T cells infiltrated by tumors are directly activated through an anti-CD3 antibody; depletion of T cells can be reversed through the PD-1 antibody on the surface, and the effector function of tumor infiltration CD8 + T cells is improved. The technical scheme can solve the technical problems that the TCR stability is not ideal and the immunosuppression state of the tumor microenvironment is difficult to overcome, and has ideal application and popularization prospects.

Provided herein are variant α4β7 integrin antibodies and methods of use.

Compositions and methods comprising integrin β8 antibodies are provided.

Provided herein is an antibody having specificity for nucleophosprotein 1 (NPM1), which is capable of binding to nucleophosprotein 1 located on the surface of a cell; and antibody-drug conjugates (ADCs) comprising such antibodies are provided. Also provided herein are methods of treating a cancer in which NPM1 is expressed on the surface of a cancer cell by administering to a subject an NPM1-binding antibody or antibody conjugate as described herein and a chemotherapeutic drug.

To provide an anti-mutant calreticulin (mutCALR) antibody.SOLUTION: An anti-mutant calreticulin (mutCALR) antibody is provided. The antibody comprises a heavy chain variable region (VH) comprising a VH CDR1, a VH CDR2 and a VH CDR3. The antibody comprises a light chain variable region (VL) comprising a VL CDR1, a VL CDR2 and a VL CDR3. The antibody is configured to: inhibit one or more signaling pathways downstream of a thrombopoietin receptor (MPL) in a cell expressing human mutant CALR; inhibit oncogenic cell proliferation in a cell expressing human mutant CALR; inhibit dimerization of the MPL in a cell expressing human mutant CALR; and / or inhibit binding of the MPL to human mutant CALR.SELECTED DRAWING: Figure 6

The invention discloses a carbamylated polypeptide and application thereof in preparation of a rheumatoid arthritis diagnostic kit. The invention provides a cyclization carbamylation polypeptide as shown in SEQ ID NO. 1 and SEQ ID NO. 2 or a combination of the cyclization carbamylation polypeptide and the combination of the cyclization carbamylation polypeptide and the combination. Tests prove that the cyclized carbamylation polypeptide antigens as shown in SEQ ID NO.1 and SEQ ID NO.2 independently have high diagnostic value for diagnosing the negative RA of the anti-cyclic citrullinated peptide antibody, and respectively have application prospects of being developed into diagnostic kits for the negative RA of the anti-cyclic citrullinated peptide antibody; the combination of SEQ ID NO.1 and SEQ ID NO.2 further improves the diagnosis value of the anti-cyclic citrullinated peptide protein antibody negative RA, and has the application prospect of being developed into the anti-cyclic citrullinated peptide protein antibody negative RA diagnosis kit in a combined manner.

Disclosed herein are pharmaceutical agents and compositions that activate integrin heterodimers that contain beta-1 integrin protein that specifically bind laminin protein. Such agents and compositions are useful for treating diseases related to muscle malfunction, including muscular dystrophies.

The invention belongs to the technical field of immunological detection, and particularly relates to an antibody for resisting porcine pseudorabies virus glycoprotein gB and application of the antibody. The antibody is a first antibody or a second antibody, amino acid sequences of light chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.3-5, and amino acid sequences of heavy chains CDR1-3 of the first antibody are respectively shown as SEQ ID NO.8-10; the amino acid sequences of light chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.13-15, and the amino acid sequences of heavy chains CDR1-3 of the second antibody are respectively as shown in SEQ ID NO.18-20. The antibody and the PRV glycoprotein gB have good reactivity, recognition specificity and binding sensitivity, the detection sensitivity and accuracy of the gB protein or the anti-gB protein antibody are improved, and an antibody tool with excellent performance is provided for qualitatively or quantitatively evaluating the immune effect of swine herd vaccines and detecting the content of porcine pseudorabies virus antigens in a sample.

The present invention relates to: a recombinant polypeptide comprising a bromodomain variant; a chimeric antigen receptor comprising the bromodomain variant in an intracellular signaling domain; a gene construct comprising a nucleotide sequence encoding the recombinant polypeptide or the chimeric antigen receptor; a cell or an immune cell, each expressing the recombinant polypeptide or the chimeric antigen receptor; a pharmaceutical composition for the prevention or treatment of cancer, comprising the immune cell; a composition for degrading the recombinant polypeptide or chimeric antigen receptor of the immune cell, the composition comprising a PROTAC compound as an active ingredient; and a kit for the prevention or treatment of cancer, comprising the pharmaceutical composition and the PROTAC compound.

Provided herein are variant α4β7 integrin antibodies and methods of use.

An anti-ROR1 antibody, an antibody-drug conjugate containing the antibody, a pharmaceutical composition and medical product containing the antibody-drug conjugate, and a method for preparing the antibody-drug conjugate, and the use thereof. The antibody-drug conjugate can be effectively used for treating and / or preventing ROR1 positive tumors including cancers represented by hematologic neoplasms and solid tumors, such as breast cancer and bladder cancer.

The invention discloses application of astrocyte-derived extracellular vesicles carrying Tau in auxiliary diagnosis of progressive suprakaryotic paralysis, and belongs to the technical field of biomedicine. The specific Tau protein antibody and the anti-glutamic acid transporter 1 antibody are labeled by fluorescence, astrocyte-derived extracellular vesicles carrying Tau in the plasma are accurately detected, PSP patients, PD patients and healthy people can be accurately distinguished by analyzing the concentration of astrocyte-derived EVs carrying Tau in the plasma, and the kit has the advantages of high sensitivity, high sensitivity, high sensitivity and the like. An efficient PSP diagnosis biomarker and a diagnosis model are provided, and a new experience method and technical support are provided for PSP diagnosis and identification.

The invention relates to the technical field of immunochromatography, in particular to a TSYl modified magnetic time-resolved fluorescent microsphere as well as a preparation method and application thereof, and the preparation method comprises the following steps: 1) preparing a surface aminated Fe3O4 magnetic core by a hydrothermal synthesis method; (2) carrying out double-bond modification on the surface of Fe3O4 through nucleophilic substitution reaction; 3) preparing surface hydroxyl modified polymer magnetic microspheres by a seed emulsion polymerization method; 4) through nucleophilic substitution reaction, performing tosyl modification on the surface of the magnetic microsphere; 5) preparing a time-resolved fluorescent dye Eu (III) complex; and 6) embedding a rare earth complex into the microspheres by a swelling method to prepare the surface tosyl modified magnetic time-resolved fluorescent microspheres. The TSYl modified magnetic time-resolved fluorescent microspheres prepared by the method have the advantages that the particle size range is 200-400nm, the particle size is uniform, and the monodispersity is good; the antibody can be directly combined with protein / antibody without activation; good magnetic responsiveness and fluorescence intensity are realized.

This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular, Bruton tyrosine kinase (“BTK”) inhibitors, for treatment of subjects with myelin oligodendrocyte glycoprotein antibody disease (MOGAD).